AI assistant
Sending…
Protara Therapeutics, Inc. — Director's Dealing 2022
Jul 5, 2022
34057_dirs_2022-07-05_eba667a5-e79b-4ad7-85d3-977989f1fe1e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2022-07-01
Reporting Person: Bandari Jathin (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-07-01 | Common Stock | F | 682 | $3.22 | Disposed | 20318 | Direct |
Footnotes
F1: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on July 1, 2020.
More from Protara Therapeutics, Inc.
Capital/Financing Update
2026
May 28
Capital/Financing Update
2026
May 13
Interim / Quarterly Report
2026
May 13
Report Publication Announcement
2026
May 13
Regulatory Filings
2026
Mar 30
Regulatory Filings
2026
Feb 24
Capital/Financing Update
2026
Feb 2
Director's Dealing
2026
Jan 27
Director's Dealing
2026
Jan 27
Director's Dealing
2026
Jan 27